[ns] (OTCBB: WSCH) Special Investment Update

Thu Apr 18 05:17:49 2002

----3web45-MultiPart-Mime-Boundary
Content-Type: text/plain
Content-Disposition: inline

______________________________________________________________
We have recently become aware of the fact that our previous list management service erroneously failed to oversee certain remove requests. We deeply apologize for any inconvenience this may have caused and would like to offer all of our valuable customers another chance to unsubscribe from our services.
______________________________________________________________

Wall Street Stockwatch
Wasatch Pharmaceuticals: Company Update

Special Corporate Update WSCH

Company Name  Wasatch Pharmaceuticals (OTCBB: WSCH)
Current Price$0.007
52-Week High$1.95
52-Week Low$0.0045

News from Wasatch Pharmaceutical (OTCBB: WSCH) is hard to come by lately.  Gary Heesch, CEO of Wasatch, doesn't buy the idea that a press release every day is productive.  He feels "it is usually perceived as an effort to over- promote the stock."  But what about the future of WSCH?  Why should anyone buy or hold their stock with no news?
Mr. Heesch feels that past news releases and their record of Company accomplishments speak for themselves.  For example, Wasatch, now in its 18th year of research, has produced skin care products for the treatment of most common skin disorders. This puts them years ahead of the competition.
In the last 12 months, WSCH has addressed a whole new dimension in preparation for launching its products into the worldwide marketplace, so that millions of people will finally have access to therapies that allow them to remedy their skin disorders and live more normal lives. This preparation involved:

(1) A new management team with impressive individual records of creating billions of dollars in revenue for Oracle, Bausch & Lomb, and Warner Lambert.

(2) The establishment of a new AISC Distribution Center that is fully inventoried with products ready for shipment.

(3) Establishing beautiful corporate offices separate from the company's clinic.

(4) Relocation of the American Institue of Skin Care clinic to a facility designed to be the prototype for future clinics.

To cap off the last 12 months, patents were filed for five new products that will be packaged and ready for release to physicians and hospitals this year.  All of these accomplishments translate into a variety of activites and relationships that will insure the growth and stability of WSCH.

When pressed to reveal this year's plans, Mr. Heesch wants to reserve the substance of these activities until they are completed and tucked away.  He did say that existing activities and plans include the acquisition of existing medical clinics, ongoing discussion for foreign licensing, conversations with groups of physicians that can represent as many as 2,000 physicians converting their patients to Wasatch products for their skin care problems, and also a possible merger that will expand WSCH's sphere of influence in the medical community.  

As these activities come to fruition, they will be disclosed to WSCH shareholders and the public in detail. Unlike many companies struggling with today's economy, Wasatch Pharmaceutical is alive and well and working towards a productive future.

Stay tuned for plenty more to come from WSCH.

DISCLAIMER: 
Information within this email contains "forward looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21B of the Securities Exchange Act of 1934. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical fact and may be "forward looking statements."

Forward looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through the use of words such as "projects", "foresee", "expects", "will,"  "anticipates," "estimates," "believes," "understands" or that by statements indicating certain actions "may," "could," or "might" occur.  All information provided within this email pertaining to investing, stocks, securities must be understood as information provided and not investment advice. Emerging Growth Stock Alert advises all readers and subscribers to seek advice from a registered professional securities representative before deciding to trade in stocks featured within this email.  None of the material within this report shall be construed as any kind of investment advice.

In compliance with the Securities Act of 1933, Section17(b), Emerging Growth Stock Alert discloses the receipt of ten million unrestricted shares of WSCH from a third party for the publication of this report and additional services related to WSCH. Be aware of an inherent conflict of interest resulting from such compensation due to our intent to profit from the sale of these shares.  All factual information in this report was gathered from public sources, including but not limited to SEC filings, Company Press Releases, and the company's website at wasatchpharm.com. Emerging Growth Stock Alert believes this information to be reliable but can make no guarantee as to its accuracy or completeness. Use of the material within this email constitutes your acceptance of these terms.

_____________________________________________________________________________
The preceding message was sent to you as an opt-in subscriber to The Stock Refinery.
If you wish to unsubscribe please follow this link: 
http://remove.3web45.com/marketrefinery/optout.htm?message_id=14&e=ns-users@isi.edu
_____________________________________________________________________________

----3web45-MultiPart-Mime-Boundary
Content-Type: text/html
Content-Disposition: inline

<html><hr align="center">
			<div align="center"><font size="1" face="Arial, Helvetica, sans-serif">We have recently become aware of the fact that our previous list management<br>
service erroneously failed to oversee certain remove requests. We deeply apologize<br> 
for any inconvenience this may have caused and would like to offer all<br>
of our valuable customers another chance to unsubscribe from our services.</font><br></div>
			<hr align="center">
			  <P>
<TABLE height=257 cellSpacing=0 cellPadding=0 width=430>
<TBODY>
<TR>
<TD width=427 rowSpan=2>
<P>
<TABLE style="WIDTH: 487px; HEIGHT: 1978px" borderColor=#89be65 height=1978 cellSpacing=0 borderColorDark=#000000 cellPadding=7 
width=487 borderColorLight=#000000 border=2>

<TBODY>
<TR>
<TD vAlign=top borderColor=#ffffff borderColorLight=#ffffff width="100%" bgColor=#800000 borderColorDark=#ffffff height=43>
<P align=center><B><FONT face=Verdana color=#efefef size=5>Wall Street Stockwatch<BR></FONT><FONT face=Verdana color=#ffa346 
size=2>Wasatch Pharmaceuticals: Company Update</FONT></B></P></TD></TR>

<TR>
<TD vAlign=top align=left width="100%" height=372>
<BLOCKQUOTE><BR><B><FONT face=Verdana size=5><I>Special Corporate Update</I> </FONT><FONT face=Verdana color=#800000 
size=3>WSCH</FONT></B><FONT size=2><BR></FONT>

<DIV align=center>
<TABLE borderColor=#efefef height=108 cellSpacing=0 borderColorDark=#efefef cellPadding=3 width="83%" borderColorLight=#efefef 
border=1>

<TBODY>
<TR>
<TD borderColor=#800000 borderColorLight=#800000 width="35%" bgColor=#800000 borderColorDark=#800000 height=32><FONT face=Verdana 
color=#efefef size=2>Company Name&nbsp;&nbsp;</FONT></TD>

<TD vAlign=top width="165%" bgColor=#efefef height=32><B><FONT face=Verdana color=#800000 size=2>Wasatch 
Pharmaceuticals</FONT><FONT face=Verdana color=#392b55 size=1> </FONT><FONT color=#fb7d00><FONT face=Verdana 
size=1>(O</FONT></FONT><FONT face=Verdana color=#fb7d00 size=1>TCBB: WSCH)</FONT></B></TD></TR>

<TR>
<TD borderColor=#800000 borderColorLight=#800000 width="35%" bgColor=#800000 borderColorDark=#800000 height=16><FONT face=Verdana 
color=#efefef size=2>Current Price</FONT></TD>

<TD vAlign=top width="165%" bgColor=#efefef height=16><FONT face=Verdana color=#800000 size=2>$0.007</FONT></TD></TR>
<TR>
<TD borderColor=#800000 borderColorLight=#800000 width="35%" bgColor=#800000 borderColorDark=#800000 height=32><FONT face=Verdana 
color=#efefef size=2>52-Week High</FONT></TD>

<TD vAlign=top width="165%" bgColor=#efefef height=32><FONT face=Verdana color=#800000 size=2>$1.95</FONT></TD></TR>
<TR>
<TD borderColor=#800000 borderColorLight=#800000 width="35%" bgColor=#800000 borderColorDark=#800000 height=1><FONT face=Verdana 
color=#efefef size=2>52-Week Low</FONT></TD>

<TD vAlign=top width="165%" bgColor=#efefef height=1><FONT face=Verdana color=#800000 
size=2>$0.0045</FONT></TD></TR></TBODY></TABLE></DIV>

<P><FONT face=Verdana size=2>News from Wasatch Pharmaceutical <B>(OTCBB: WSCH) </B>is hard to come by lately.&nbsp; Gary Heesch, 
CEO of Wasatch, doesn't buy the idea that a press release every day is productive.&nbsp; He feels <B>"it is usually perceived as 
an effort to over- promote the stock."</B>&nbsp; But what about the future of WSCH?&nbsp; Why should anyone buy or hold their 
stock with no news?</FONT></P>

Mr. Heesch feels that past news releases and their record of Company accomplishments speak for 
themselves.&nbsp; For example, Wasatch, now in its 18th year of research, has produced skin care products for the treatment 
of most common skin disorders. This puts them years ahead of the competition.

In the last 12 months, WSCH has addressed a whole new dimension in preparation for launching its 
products into the worldwide marketplace, so that millions of people will finally have access to therapies that allow them to 
remedy their skin disorders and live more normal lives. This preparation involved: (1) A new management team with 
impressive individual records of creating billions of dollars in revenue for Oracle, Bausch &amp; Lomb, and Warner 
Lambert. (2) The establishment of a new AISC Distribution Center that is fully inventoried with products ready for 
shipment. (3) Establishing beautiful corporate offices separate from the company's clinic. (4) Relocation 
of the American Institue of Skin Care clinic to a facility designed to be the prototype for future clinics. To cap off 
the last 12 months, patents were filed for five new products that will be packaged and ready for release to physicians and 
hospitals this year.&nbsp; All of these accomplishments translate into a variety of activites and relationships that will 
insure the growth and stability of WSCH. When pressed to reveal this year's plans, Mr. Heesch wants to reserve the 
substance of these activities until they are completed and tucked away.&nbsp; He did say that existing activities and plans 
include the acquisition of existing medical clinics, ongoing discussion for foreign licensing, conversations with 
groups of physicians that can represent as many as 2,000 physicians converting their patients to Wasatch products for their 
skin care problems, and also a possible merger that will expand WSCH's sphere of influence in the medical 
community.&nbsp;&nbsp; As these activities come to fruition, they will be disclosed to WSCH shareholders and the 
public in detail. Unlike many companies struggling with today's economy, Wasatch Pharmaceutical is alive and well and working 
towards a productive future. Stay tuned for plenty more to come from 
WSCH.

&nbsp;
&nbsp;
&nbsp;
&nbsp;
&nbsp;
DISCLAIMER:&nbsp; Information within this email 
contains "forward looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21B of the 
Securities Exchange Act of 1934. Any statements that express or involve discussions with respect to predictions, expectations, 
beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical fact 
and may be "forward looking statements." Forward looking statements are based on expectations, estimates and projections at 
the time the statements are made that involve a number of&nbsp;risks and uncertainties which could cause actual results or events 
to differ materially from those presently anticipated. Forward looking statements in this action may be identified through the use 
of words such as "projects", "foresee", "expects", "will,"&nbsp; "anticipates," "estimates," "believes," "understands" or that by 
statements indicating certain actions "may," "could," or "might" occur.&nbsp; All information provided within this email 
pertaining to investing, stocks, securities must be understood as information provided and not investment advice. Emerging Growth 
Stock Alert advises all readers and subscribers to seek&nbsp;advice from a registered professional securities representative 
before deciding to trade in stocks featured within this email.&nbsp; None of the material within this report shall be construed as 
any kind of investment advice. In compliance with the Securities Act of 1933, Section17(b), Emerging Growth Stock Alert 
discloses the receipt of ten million unrestricted shares of WSCH from a third party for the publication of this report and 
additional&nbsp;services related to WSCH. Be aware of an inherent conflict of interest 
resulting from such compensation due to our intent to profit from the sale of these shares.&nbsp; All&nbsp;factual information in 
this report was gathered from public sources, including but not limited to SEC filings, Company Press Releases, and the company's 
website at wasatchpharm.com.&nbsp;Emerging Growth Stock Alert believes this information to 
be reliable but can make no guarantee as to its accuracy or completeness. Use of the material within this email constitutes your 
acceptance of these terms. &nbsp;</BLOCKQUOTE></TD></TR></TBODY></TABLE>

<P></P>
<P><A href="" target=new></A></P>
<P>&nbsp;</P></TD>
<TD width=2>&nbsp;</TD>
<TD width=3>&nbsp;</TD></TR>
<TR>
<TD width=2>&nbsp;</TD>
<TD width=3>&nbsp;</TD></TR></TBODY></TABLE></P>

<hr align="center">
			<div align="center">
<font size="1" face="Arial, Helvetica, sans-serif">The preceding message was sent to you as an opt-in subscriber to The Stock Refinery.<br>
If you wish to unsubscribe please follow this link: <br>
<a href="http://remove.3web45.com/marketrefinery/optout.htm?message_id=14&e=ns-users@isi.edu">http://remove.3web45.com/marketrefinery/optout.htm?message_id=14&e=ns-users@isi.edu</a></font></div>
			<hr align="center">
<img src="http://remove.3web45.com/marketrefinery/messagetrack.php?message_id=14&CID=5933631" border="0" width="1" height="1">

</html>

----3web45-MultiPart-Mime-Boundary--